Affiliations 

  • 1 UKM Medical Molecular Biology Institute (UMBI), UKM Medical Center, Jalan Yaacob Latiff, Cheras 56000, Kuala Lumpur, Malaysia
Future Oncol, 2018 Dec;14(29):3085-3095.
PMID: 30468082 DOI: 10.2217/fon-2018-0303

Abstract

Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.